Press Release Summary = Pascal Girin is appointed Member of Board and Benjamin Abrat, co-founder, moves to Cambridge, MA, as VP Business Development and Strategy.
Press Release Body = Paris (France), Cambridge (MA, USA) - November 6th , 2006 - MAUNA KEA TECHNOLOGIES, a medical technology company specialized in the development of minimally invasive in vivo microscopy solutions, announced today that M. Pascal Girin has been appointed to the Board of Directors and that Benjamin Abrat, co-founder of the company, is taking new responsibilities as VP Business Development and Strategy based in the company's offices in Cambridge (Massachusetts, USA).
« We are very pleased to welcome Pascal to the Board», said Sacha Loiseau. \"His proven track record and experience of fast growing companies in the medical device industry are invaluable to us ». Pascal Girin has more than 20 years of experience in the development, marketing and sales of medical devices. Since July 2005, M. Girin has been serving as President, International of ev3, a leading worldwide medical device company focused on endovascular technologies for the minimally invasive treatment of vascular diseases and disorders. Prior to this position, Mr. Girin served as General Manager, Europe of ev3, since September 2003 and as VP Europe for the Baxter Healthcare BioScience Corporation prior to that.
Mauna Kea Technologies is also announcing today the installation of Benjamin Abrat, co-founder of the company, in Cambridge, MA, USA where the company already has its North-American office.
« With Benjamin Abrat spearheading our efforts in the US, we are confident that Mauna Kea Technologies will energetically build its North American clinical and marketing activities. Mauna Kea Technologies is establishing key partnerships to accelerate the dissemination of its instruments and we expect exciting announcements in this domain before year end thanks to Benjamin's work "in situ" ! », added Sacha Loiseau.
Mauna Kea Technologies launched its fibered confocal fluorescence microscopy system for gastro-intestinal applications (Cellvizio®-GI) last may after having recorded very promising results in clinical trials carried out in the United States, Japan, Germany and the United Kingdom and, more recently, its Cellvizio®-LUNG solution, which is the first instrument ever capable of imaging the distal airways at the microscopic level.
- END -
About MAUNA KEA TECHNOLOGIES
Founded in 2000 and run by Sacha Loiseau and Benjamin Abrat, MAUNA KEA TECHNOLOGIES is the inventor of the Cellvizio, the world's smallest microscope. The Cellvizio enables microscopic observations in real time either on living animals for research applications or on patients for medical applications, in particular during GI endoscopy and bronchoscopy. Based in Paris and Cambridge, MA, the company currently employs 45 people.
2025
